A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Inclusion Criteria:
Exclusion Criteria:
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have taken any of the following antihyperglycemic medications within 90 days before screening:
Have had within 90 days prior to screening:
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Have taken medications or alternative remedies intended for weight loss within 90 days of screening
LillyTrials@Lilly.com317-615-4559
clinical_inquiry_hub@lilly.com
Birmingham, Alabama 35209, United States
205-870-4343
Miami, Florida 33138, United States
Winter Park, Florida 32789, United States
Metairie, Louisiana 70006, United States
Wilmington, North Carolina 28403, United States
Pittsburgh, Pennsylvania 15243, United States
Buenos Aires, C1419AHN, Argentina
Buenos Aires, C1425AGC, Argentina
CABA, 1204, Argentina
5491121559419
Luoyang Shi, 471023, China
13653880139
Bünde, 32257, Germany
Münster, 48153, Germany
Belgavi, 590019, India
Kasuya-gun, 811-2310, Japan
81120023812
Setagaya-ku, 155-0031, Japan
81120023812
Guadalajara, 44600, Mexico
Guadalajara, 44670, Mexico
Bialystok, 15445, Poland
Krakow, 31-261, Poland
Lodz, 90-338, Poland
Kaohsiung Niao Sung Dist, 83301, Taiwan
+886912159389
256-708-2826
818-222-6868
760-466-1520
415-461-1585
562-598-0600 ext 205
310-693-5000
661-371-7272
619-660-9068
925-930-7267
720-368-4865
203-374-9816
386-278-8000
401-773-7855
904-621-0390
352-341-2100
904-730-0101
786-772-0411
305-226-3933
352-383-8222
954-237-3799
407-740-8078
470-403-4755
808-526-0303
847-663-8540
463-271-3050
504-455-1310
410-730-3399
508-720-2015
636-220-1200
417-883-7889
505-224-7407
516-574-9232
336-574-8020
252-515-0050
701-232-7705
412-942-0023
724-438-1479
843-849-1880
361-885-0448
817-263-0007
713-779-5494
214-693-0904
9729991155 x103
210-692-7157
385-271-0684
801-816-1010
(54 11) 48166733
541160884234
08003450697
541145143400
541145740870
5401148019001
54 9 351 4245162
54 9 3413 34-8021
543412384171
3416176661
13910978815
13911080328
13594028475
86-13956099720
13767035719
18951762960
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
523312044280
+523336153477
523336422886
9992211846
8140401554
48856520318
48696268565
48608202021
48126237122
607536360
48603787884
48728814934
48 32 271 25 11
7877467057
787-278-1576
00421908956445
00421905565208
421948014007
421 35 6420 746
421423810145
421907230520
82314124274
886-7-3121101 ext 7741
0223123456
886228757516